Guidance Documents Do Not Favor Big Pharma
In 2025, a surge of FDA guidance updates signaled a broader shift in the clinical trial ecosystem. They marked...
In 2025, a surge of FDA guidance updates signaled a broader shift in the clinical trial ecosystem. They marked...
At the 2025 Veeva R&D and Quality Summit Europe, Martin Helling, Executive Director of the One Medicine Platform at...
Artificial intelligence (AI) is reshaping clinical trials, offering new efficiencies and insights. Rohit Nambisan, CEO of Lokavant, shares his...
In this interview with Dr. Seema Rajsingh, Executive Medical Director and Jarem Edwards, Clinical Scientist – Early Drug Development...
The global obesity epidemic has shifted from a public health issue to a fiercely competitive pharmaceutical frontier. With GLP-1...
In this conversation with Jeffrey Sorenson, CEO at Yunu, we explore the transformative potential of treating imaging data as...
In this conversation, Thad Wolfram, Chief Strategy Officer of EmVenio Research and PCM Trials, shares his insights on the...
As GenAI gains traction across life sciences, the conversation is rapidly shifting from potential to practicality. Yet, many organizations...
In this interview, Anca Copaescu, Founder and CEO at Strategikon, explores the complexities of clinical trial management. Anca provides...
In this interview, Rachael Thomas Higgins, Chief Commercial Officer of PicnicHealth, offers her perspective on the pivotal role of...